Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1813 | Hydroxychloroquine combined with Azithromycin Wiki | 1.00 |
| drug1515 | Favipiravir (3600 mg + 1600 mg) Wiki | 1.00 |
| drug1513 | Favipiravir (3200 mg + 1200 mg) combined with Azithromycin Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003141 | Communicable Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.05 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is an open-label, multicenter, parallel-group, randomized, phase III trial that evaluates the efficacy and safety of hydroxychloroquine and favipiravir in the treatment of patients with possible or confirmed COVID-19 observed within the last 5 days. 1000 patients will be randomized in 2:1:2:2:2:1 ratio and divided into six groups.
Description: The evaluation of recovery (discharge) period until 14th day after administration.
Measure: Time to recovery (discharge) Time: 14 daysDescription: The evaluation of decrease in viral load until 14th day after administration.
Measure: Decrease in viral load Time: 14 daysDescription: Number/characteristics of Adverse Event (AE), Serious Adverse Event (SAE) and discontinuation of treatment due to study drug from baseline until the end of study
Measure: Adverse Event (AE), Serious Adverse Event (SAE) and discontinuation of treatment Time: 14 daysDescription: Clinical evaluation of occurrence of lymphopenia from baseline until the end of study.
Measure: Frequency of occurrence of lymphopenia from baseline Time: 14 daysDescription: Clinical evaluation of occurrence of thrombocytopenia from baseline until the end of study.
Measure: Frequency of occurrence of thrombocytopenia from baseline Time: 14 daysDescription: Clinical evaluation of ALT levels from baseline until the end of study.
Measure: Changes in alanine aminotransferase (ALT) levels from baseline Time: 14 daysDescription: Clinical evaluation of AST levels from baseline until the end of study.
Measure: Changes in aspartate aminotransferase (AST) levels from baseline Time: 14 daysDescription: Clinical evaluation of CRP levels from baseline until the end of study.
Measure: Changes in C-reactive protein (CRP) levels from baseline Time: 14 daysDescription: Clinical evaluation of D-dimer levels from baseline until the end of study.
Measure: Changes in level of D-dimer levels from baseline Time: 14 daysDescription: Clinical evaluation of PT values for blood to coagulate from baseline until the end of study.
Measure: Changes in prothrombin time (PT) values from baseline Time: 14 daysDescription: Clinical evaluation of PTT values for blood to coagulate from baseline until the end of study.
Measure: Changes in partial thromboplastin time (PTT) values from baseline Time: 14 daysDescription: Clinical evaluation of systolic and diastolic blood pressure levels from baseline until the end of study.
Measure: Changes in blood pressure from baseline Time: 14 daysDescription: Clinical evaluation of respiratory rate levels from baseline until the end of study.
Measure: Changes in respiratory rate from baseline Time: 14 daysDescription: Clinical evaluation of pulse oxymetry levels from baseline until the end of study.
Measure: Changes in pulse oxymetry from baseline Time: 14 daysDescription: Clinical evaluation of changes in fever from baseline until the end of study.
Measure: Changes in fever from baseline Time: 14 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports